Advanced search
Publication Cover
Expert Review of Hematology Volume 8, 2015 - Issue 2
Submit an article Journal homepage
3,819
Views
19
CrossRef citations to date
0
Altmetric
Editorial

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

Melanie JanningDepartment of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Isabel Ben-BatallaDepartment of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
&
Sonja LogesDepartment of Hematology and Oncology, BMT with Section of Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyCorrespondence[email protected]
Pages 135-138 | Published online: 12 Jan 2015

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Kiran Naqvi & Farhad Ravandi. (2019) FLT3 inhibitor quizartinib (AC220). Leukemia & Lymphoma 60:8, pages 1866-1876.
Read now
Roya Ahmadi, Bakhtyar Sepehri & Raouf Ghavami. (2019) Development linear and non-linear QSAR models for predicting AXL kinase inhibitory activity of N-[4-(quinolin-4-yloxy)phenyl]benzenesulfonamides. Journal of Receptors and Signal Transduction 39:3, pages 264-275.
Read now
Kiran Naqvi, Marina Konopleva & Farhad Ravandi. (2017) Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Expert Review of Hematology 10:10, pages 863-874.
Read now
Naval Daver, Jorge Cortes, Hagop Kantarjian & Farhad Ravandi. (2016) Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Review of Hematology 9:5, pages 433-445.
Read now
Håkon Reikvam, Michelle Hauge, Annette K Brenner, Kimberley Joanne Hatfield & Øystein Bruserud. (2015) Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Review of Hematology 8:3, pages 299-313.
Read now

Articles from other publishers (14)

Chinmay Malvankar & Dileep Kumar. (2022) AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188786.
Crossref
Jenying Deng & Jason B. Fleming. (2022) Inflammation and Myeloid Cells in Cancer Progression and Metastasis. Frontiers in Cell and Developmental Biology 9.
Crossref
Caspar V. Bumm, Matthias Folwaczny & Uta C. Wölfle. (2020) Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib—a case report. Oral and Maxillofacial Surgery 24:3, pages 353-358.
Crossref
Serena Chew, Melissa C. Mackey & Elias Jabbour. (2020) Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. Therapeutic Advances in Hematology 11, pages 204062072093061.
Crossref
Ting Yuan, Baowen Qi, Zhongliang Jiang, Wenjuan Dong, Lei Zhong, Lan Bai, Rongsheng Tong, Jiying Yu & Jianyou Shi. (2019) Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade. European Journal of Medicinal Chemistry 178, pages 468-483.
Crossref
Xinrui Yang, Jinlong Shi, Xinpei Zhang, Gaoqi Zhang, Jilei Zhang, Siyuan Yang, Jing Wang, Xiaoyan Ke & Lin Fu. (2019) Expression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. Bioscience Reports 39:5.
Crossref
Lea Landolt, Jessica Furriol, Janka Babickova, Lavina Ahmed, Øystein Eikrem, Trude Skogstrand, Andreas Scherer, Salwa Suliman, Sabine Leh, James B. Lorens, Gro Gausdal, Hans‐Peter Marti & Tarig Osman. (2019) AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction . Physiological Reports 7:10, pages e14091.
Crossref
Guiling Wu, Zhiqiang Ma, Yicheng Cheng, Wei Hu, Chao Deng, Shuai Jiang, Tian Li, Fulin Chen & Yang Yang. (2018) Targeting Gas6/TAM in cancer cells and tumor microenvironment. Molecular Cancer 17:1.
Crossref
Samuel H. MyersCarolin TempsDouglas R. HoustonValerie G. BruntonAsier Unciti-Broceta. (2018) Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening. Journal of Medicinal Chemistry 61:5, pages 2104-2110.
Crossref
Rahul Kumar, P. Sonika Godavarthy & Daniela S. Krause. (2018) The bone marrow microenvironment in health and disease at a glance. Journal of Cell Science 131:4.
Crossref
Masamichi Mori, Naoki Kaneko, Yoko Ueno, Masaki Yamada, Ruriko Tanaka, Rika Saito, Itsuro Shimada, Kenichi Mori & Sadao Kuromitsu. (2017) Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investigational New Drugs 35:5, pages 556-565.
Crossref
Guiling Wu, Zhiqiang Ma, Wei Hu, Dongjin Wang, Bing Gong, Chongxi Fan, Shuai Jiang, Tian Li, Jianyuan Gao & Yang Yang. (2017) Molecular insights of Gas6/TAM in cancer development and therapy. Cell Death & Disease 8:3, pages e2700-e2700.
Crossref
Paolo Bernasconi, Mirko Farina, Marina Boni, Irene Dambruoso & Celeste Calvello. (2016) Therapeutically targeting SELF ‐reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? . American Journal of Hematology 91:5, pages 507-517.
Crossref
Peng Cheng, Emma Phillips, Sung-Hak Kim, David Taylor, Thomas Hielscher, Laura Puccio, Anita B. Hjelmeland, Peter Lichter, Ichiro Nakano & Violaine Goidts. (2015) Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells. Stem Cell Reports 4:5, pages 899-913.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.